| URL | https://www.biospace.com/article/releases/nexus-ph |
| Source | Bio Space |
| Date Published | 03/26/2021 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Nexus Pharmaceuticals Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 400 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 250 |
| City reshored to: | Pleasant Prairie |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | specialty and generic injectables |